:
By working directly in the GI tissue, it may achieve higher local concentrations than systemic drugs without increasing the risk of body-wide infections. sor102
:
One patient reported a mild TEAE of catheter site pain and another patient reported a mild TEAE of headache in the placebo group. ... ScienceDirect.com Study Details | NCT06080048 - Clinical Trials SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, an... Clinical Trials.gov Reaching the therapeutic ceiling in IBD: Can Advanced Combination ... SOR102 was well tolerated across all doses, with no systemic exposure of the drug or its monomers, supporting its gut-targeted act... ScienceDirect.com Publications - Sorriso Pharmaceuticals The Lancet Gastroenterology & Hepatology. | 2025. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and i... Sorriso Pharmaceuticals Safety and pharmacokinetics of SOR102, an oral bispecific ... Dec 22, 2025 — : By working directly in the GI tissue,